Cree, B., Bennett, J., Kim, H., Weinshenker, B., Pittock, S., Wingerchuk, D., . . . Katz, E. (2019). Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Elsevier.
Цитирование в стиле Чикаго (17-е изд.)Cree, BAC, et al. Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-blind, Randomised Placebo-controlled Phase 2/3 Trial. Elsevier, 2019.
Цитирование MLA (9-е изд.)Cree, BAC, et al. Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-blind, Randomised Placebo-controlled Phase 2/3 Trial. Elsevier, 2019.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.